Reduced pancreatic polypeptide response is associated with early alteration of glycemic control in chronic pancreatitis.

C-peptide response Chronic pancreatitis Glucose intolerance Oral glucose tolerance test Pancreatic polypeptide response Pancreatogenic diabetes

Journal

Diabetes research and clinical practice
ISSN: 1872-8227
Titre abrégé: Diabetes Res Clin Pract
Pays: Ireland
ID NLM: 8508335

Informations de publication

Date de publication:
Feb 2020
Historique:
received: 21 10 2019
revised: 25 11 2019
accepted: 20 12 2019
pubmed: 27 12 2019
medline: 4 6 2020
entrez: 27 12 2019
Statut: ppublish

Résumé

To study the incidence of glucose intolerance in CP patients without diabetes by performing oral glucose tolerance test (OGTT). We screened consecutive Indian CP patients without diabetes over 6 months by performing OGTT and correlated with physical characteristics and glycated hemoglobin (HbA1c). We also compared c-peptide and pancreatic polypeptide response in different groups based on OGTT. Relevant statistical tests were performed. P < 0.05 was considered significant. Total of 171 patients were screened. Mean duration of CP was 5.03 ± 4.32 years. 55 were detected to have prediabetes and 40 DM on OGTT. CP patients with diabetes and prediabetes had significantly dilated pancreatic duct compared to non-diabetic CP (4.2 ± 2.7 mm, 3.6 ± 2.7 mm, 2.84 ± 2.25 mm; p = 0.018). Fasting blood glucose (FBS) and 2-hour OGTT were 109.35 ± 19.06, 97.47 ± 11.94, 85.24 ± 9.95 and 236.13 ± 31.42, 154.65 ± 19.53, 112.89 ± 16.32 in patients with DM, prediabetes and CP patients without diabetes (p < 0.0001). There was a good c-peptide response (p = 0.001) and reduced pancreatic polypeptide response (p = 0.003) in CP patients compared to controls. Early in the course of disease reduced pancreatic polypeptide response in the presence of good c-peptide response may result in development of DM.

Identifiants

pubmed: 31877344
pii: S0168-8227(19)31524-4
doi: 10.1016/j.diabres.2019.107993
pii:
doi:

Substances chimiques

Blood Glucose 0
C-Peptide 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

107993

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors whose names are listed immediately above certify that they have NO affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.

Auteurs

Mohsin Aslam (M)

Clinical Endocrinologist, Asian Institute of Gastroenterology, Somajiguda, Hyderabad, India. Electronic address: mohsin.aslam2602@gmail.com.

K Vijayasarathy (K)

Asian Healthcare Foundation, Somajiguda, Hyderabad, India.

Rupjyothi Talukdar (R)

Clinical Pancreatologist, Asian Institute of Gastroenterology, Somajiguda, Hyderabad, India.

M Sasikala (M)

Director, Research, Institute of Basic Sciences and Translational Research, Asian Healthcare Foundation, Somajiguda, Hyderabad, India.

D Nageshwar Reddy (D)

Chairman and Chief of Gastroenterology, Asian Institute of Gastroenterology, Somajiguda, Hyderabad, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH